BY CHRISTOPHER DUE KARLSSON
-
US health clinic Calibrate changes management
Adjust has actually changed the business’s chief executive officer and made a number of various other administration modifications, records market media Endpoints Information…
-
Demant surpasses Novo Nordisk on list of Europe’s best employers
The clinical gadget business Coloplast additionally shows up on the checklist.
-
Novo Nordisk needs a new CEO: Headhunter gives three bids for Fruergaard’s replacement
Henrik Brabrand from the employment company Albright Allies indicates 2 outside prospects, and he additionally highlights a solitary interior prospect.
-
For the first time since 2018: Leo Pharma achieves billion-kroner profit in Q1
The big earnings is mostly as a result of the manage US-based Gilead Sciences that Leo Pharma authorized previously this year.
-
Leo Pharma achieves positive results with antibody therapy in phase 2b trial
The goal of the research was to evaluate the performance and safety and security of various dosages of the therapy in grownups with modest to serious atopic dermatitis.
-
RealMan Showcases Cutting-Edge Embodied Robotics at Automate 2025 | RoboticsTomorrow
RealMan Showcases Lowering-Edge Embodied Robotics at Automate 2025 RealMan Robotics debuts shiny embodied robotic arms, modular platforms, and AI-powered medical solutions at Automate 2025, highlighting innovations for manufacturing, study, and comely healthcare. RealMan Robotics, a main innovator in embodied intelligence and modular robotic systems, made a extremely efficient affect at Automate 2025, North The US’s
-
New management team in Leo Pharma: Two directors let go and a new hired from Novo Nordisk
chief executive officer states he lags the choice to alter Leo Pharma’s administration group as component of a brand-new approach.
-
Leo Pharma achieves positive results with antibody therapy in phase 2b trial
The aim of the study was to assess the effectiveness and safety of different doses of the treatment in adults with moderate to severe atopic eczema.
-
Novo Nordisk lowers its full-year guidance
The pharmaceutical business introduced this about its very first quarter results on Wednesday early morning CEST.
-
Zealand Pharma weighing options to market obesity drug faster after Roche deal
chief executive officer stresses, nonetheless, that the firm will certainly not be leaping via hoops.
